Acute decompensated heart failure

Reading File

Finding Sources

Searching PubMed

"acute decompensated heart failure" AND management

Reading File

Loading Image

Reading File

Here is a comprehensive overview of Acute Decompensated Heart Failure (ADHF):

Acute Decompensated Heart Failure (ADHF)

Definition & Epidemiology

ADHF is a heterogeneous clinical syndrome resulting from the confluence of decreased cardiac performance, renal dysfunction, and altered vascular compliance — severe enough to necessitate hospitalization. It carries a high burden:

In-hospital mortality: ~5%
1-year mortality: ~20%
Readmission within 6 months: ~50%
Combined adverse events at 12 months (CV death, HF hospitalization, MI, stroke, sudden death): ~50%

Precipitating Factors

Identifying the trigger is the first principle of management:

Category	Examples
Medication non-adherence	Missed diuretics, dietary salt excess
Drugs that worsen HF	NSAIDs, thiazolidinediones, TNF inhibitors, certain antidepressants, cancer therapies
Ischemia	Coronary artery disease (investigate invasively or noninvasively)
Arrhythmias	Atrial fibrillation, ventricular tachycardia → cardioversion, ablation
Valvular disease	Readily identified on echocardiography
Infection / PE	Sepsis, pulmonary thromboembolism

Clinical Phenotypes & Management Framework

ADHF phenotypes and management principles

Figure: ADHF phenotypes with associated treatments — Harrison's Principles of Internal Medicine 22E

Phenotype	Key Features	Primary Treatment
Hypertensive	Elevated BP, usually NOT volume overloaded	IV vasodilators (nitroglycerin, nitroprusside, nesiritide)
Normotensive (volume overloaded)	Typical congestion, edema	IV loop diuretics
Pulmonary edema	Severe hypoxia, congestion	O₂ + noninvasive ventilation, vasodilators, diuretics, opiates
Low-output	Cool extremities, low pulse pressure, cardiorenal syndrome	Vasodilators ± inotropes; hemodynamic monitoring
Cardiogenic shock	Hypotension, end-organ failure, extreme distress	Catecholamines (inotropes) + mechanical circulatory support (IABP, percutaneous VAD, ultrafiltration)

Volume Management

IV Loop Diuretics

First-line for congestion relief; essential when oral absorption is impaired
Bolus vs. continuous infusion: No clear difference in clinical trials (DOSE trial)
High vs. low dose: No significant difference in symptom scores, though high dose improved decongestion
Sequential nephron blockade: Add thiazide (metolazone or chlorothiazide) for diuretic resistance — increases risk of hypokalemia
Acetazolamide + loop diuretic (ADVOR trial): Greater decongestion but no reduction in readmissions or mortality
Torsemide vs. furosemide: TRANSFORM-HF showed no mortality/morbidity advantage despite better oral bioavailability

Endpoints for euvolemia: Normalized JVP, cleared pulmonary rales, resolution of S3 gallop, peripheral edema, ascites; predischarge BNP/NT-proBNP predicts postdischarge risk

IV Vasodilators

Nitroglycerin, nitroprusside, nesiritide (recombinant BNP)
Counteract neurohormonal activation (sympathetic tone, angiotensin II, aldosterone, endothelin, AVP)
Most useful in hypertensive phenotype

Ultrafiltration (Aquapheresis)

Controlled fluid removal with electrolyte-neutral effect
CARRESS-HF trial: No superiority over stepped pharmacologic care; higher adverse events
Reserved for diuretic-refractory cases

Pulmonary Artery Catheter — When to Use

Routine use is not recommended. Restrict to:

Low-output HF or cardiogenic shock needing vasopressor/mechanical support
Diuretic-resistant or refractory cases
Cardiorenal dysfunction where goals are unclear
Known/suspected pulmonary arterial hypertension

High-risk markers: BUN >43 mg/dL, SBP <115 mmHg, creatinine >2.75 mg/dL, elevated BNP/troponin

Cardiorenal Syndrome

Occurs in ~30% of hospitalized ADHF patients
Not simply reduced renal perfusion — neurohormonal, elevated intraabdominal pressure, and renal venous congestion all contribute
Worsening GFR with diuresis does not necessarily worsen prognosis if decongestion is achieved
Severe low-output state: short-term inotropic therapy or mechanical support to bridge to definitive therapy

Inotropic & Vasopressor Therapy

Dobutamine (β₁ agonist): increases contractility; first-line inotrope in low-output HF
Dopamine: dose-dependent effects; lower doses renal/vasodilatory, higher doses vasopressor
Milrinone (PDE inhibitor): combined inotropic + vasodilatory; useful in β-blocker–treated patients
Norepinephrine/vasopressin: reserved for cardiogenic shock with refractory hypotension
Levosimendan: calcium sensitizer with inotropic and vasodilatory properties; approved in many countries (not US)

Discharge & Transition Therapy

Key evidence-based strategies at discharge:

Trial	Intervention	Result
PIONEER-HF	Sacubitril-valsartan (ARNI) vs. enalapril pre-discharge	Greater NT-proBNP reduction; lower death + readmission at 8 weeks
EMPULSE	Empagliflozin (SGLT-2i) pre-discharge	Improved hierarchical clinical composite at 90 days
STRONG-HF	Intensive post-discharge follow-up + rapid uptitration of GDMT	Lower death + readmission at 180 days (regardless of EF)

Before discharge: Patient education on fluid/salt restriction, daily weights, symptom recognition, early follow-up (within 7 days reduces readmission)

Failed or Disappointing Therapies

Rolofylline (adenosine A1 antagonist): no benefit in PROTECT trial
Tolvaptan (vasopressin-2 antagonist): no mortality/morbidity benefit in EVEREST trial
Bosentan (endothelin antagonist): worsened HFrEF
Moxonidine (central sympatholytic): worsened outcomes

Recent Evidence (2024–2025)

Prehospital lung ultrasound for diagnosing ADHF: high diagnostic accuracy (SR/MA, PMID 38522242)
Subcutaneous furosemide: emerging role in outpatient HF management (SR, PMID 39352583)
Restricted sodium intake during hospitalization: SR/MA shows no clear mortality benefit (PMID 40450575)

Sources: Harrison's Principles of Internal Medicine 22E (2025), Brenner & Rector's The Kidney

This is a shared conversation. Sign in to Orris to start your own chat.